Digestive cancers: mechanisms, therapeutics and management.

Signal Transduct Target Ther · 2025 · PMC11733248 · PMID 39809756

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Overall survival was prolonged in the ivosidenib group with 10.3 versus 7.5 months, but this did not reach statistical significance due to the crossover design. 216 Based on these results, ivosidenib was approved by the FDA in 2022.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.